EN DE
Watch Lexeo Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Lexeo Therapeutics, Inc. (LXEO) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Lexeo Therapeutics, Inc. stock $1.73, price $2.89, that is 40.3% below the price, quality 36 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

LT Lexeo Therapeutics, Inc. logo Thin data Nov 8, 2026

Lexeo Therapeutics, Inc.

LXEO · US
Very expensive, weak quality

Our calculation puts a fair price 40% below what the stock costs today.

Mixed vs. peers (4/7)
Insiders sold $323,329 (6M)
Fair value $1.73 · Strongly overvalued
Quality 36/100
Weak Growth (revenue YoY −60.5 %/yr in USD)
Negative free cash flow
Narrow moat 8/100 · thin data
Thin data
⚠ Dilution
Watch Lexeo Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$18.76 $1.79 Fair Value $1.73 Nov 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

36‑month range $1.79 – $18.76 · fair‑value band $1.14 – $2.15 · the $2.89 price screens above the $1.73 fair value. As of Nov 8, 2026.

Follow Lexeo Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Lexeo Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.

Show moreShow less

Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy.

The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy.

In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease.

The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate.

The company was founded in 2017 and is headquartered in New York, New York.

Stock analysis

Lexeo Therapeutics, Inc. (LXEO) currently trades at $2.89, while our model-based Fair Value estimate is $1.73, 40% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.14 (bear) to $2.15 (bull), the price of $2.89 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Lexeo Therapeutics, Inc. Common Stock reported revenue of $0 in FY2025 versus $1.7M in FY2021. Reported net income was −$100.0M in FY2025.

Key figures

Market cap $247M Micro · EPS (TTM) $−1.02 · Return on equity −46.8% · Return on assets (EBIT) −52.2% (5-year average) · Free cash flow −$99.0M · Net cash $55.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 73% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −40%, LXEO screens richer than that median.

Fair Value models

Bear $1.14 Fair Value $1.73 Bull $2.15
Price $2.89 · Downside -40.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.34 $2.03 $2.53 52
All 1 models by family
Asset-Based
NCAV (Graham) $1.34 $2.03 $2.53 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 6
How calm the share price moves, does not count
Price momentum 1
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 4 officers or directors sold shares worth $323,329 and none bought.

  • SaleRichard Nolan TownsendChief Executive Officer, Director6× since Nov 18, 2025: 98,934 shares, avg. $5.44$538,012Aug 18, 2026
  • SaleJose Manuel OteroChief Operating Officer5× since Nov 18, 2025: 11,009 shares, avg. $5.45$59,959Aug 18, 2026
  • SaleLouis Edward TamayoChief Financial Officer2× since Jul 1, 2026: 8,758 shares, avg. $4.69$41,053Aug 18, 2026
  • SaleNarinder Pal BhallaChief Medical Officer22,306 shares at $4.42$98,593Jul 1, 2026
  • SaleEric AdlerChief Medical Officer615 shares at $9.27$5,701Nov 18, 2025
  • SaleJenny RobertsonChief Legal Officer549 shares at $9.27$5,089Nov 18, 2025
  • SaleTai Sandi SeeChief Development Officer386 shares at $9.27$3,578Nov 18, 2025

Plus 7 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LXEO screens overvalued: fair value 40% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Lexeo Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 36 · Below median
Fair Value upside −40.3% · Above median
Profitability
Return on assets −37.2% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.00× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs LXEO
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs LXEO
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs LXEO
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs LXEO
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs LXEO
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs LXEO
argenx SE ARGX $927.21 $908.40 −2% vs LXEO
CSL Limited CSL A$200.77 A$183.04 −9% vs LXEO
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs LXEO
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs LXEO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lexeo Therapeutics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Lexeo Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/LXEO

Frequently asked questions

Is Lexeo Therapeutics, Inc. (LXEO) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $1.73 versus a price of $2.89, about 40% lower (overvalued).
What is the fair value of LXEO?
Our model-based fair value for Lexeo Therapeutics, Inc. is $1.73 (as of Nov 8, 2026), built from audited fundamentals. The current price: $2.89.
What is the quality score of LXEO?
Lexeo Therapeutics, Inc. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lexeo Therapeutics, Inc. (LXEO)?
Our model-based price target is the fair value of $1.73 (as of Nov 8, 2026) from 1 valuation models. Cautious scenario $1.14, optimistic scenario $2.15. It is a calculation from audited fundamentals, not an analyst target.
What is the Lexeo Therapeutics, Inc. Common Stock stock forecast for 2026?
Our models put fair value at $1.73, about 40% lower versus a price of $2.89 (overvalued). Cautious scenario $1.14, optimistic scenario $2.15. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Lexeo Therapeutics, Inc. (LXEO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lexeo Therapeutics, Inc. it is $1.73 per share (as of Nov 8, 2026), against a price of $2.89. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Lexeo Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 8, 2026, LXEO trades above its calculated fair value: price $2.89, fair value $1.73, a gap of about −40% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LXEO?
No. The price is what the market pays today ($2.89); the fair value is what the company's own numbers justify ($1.73). For Lexeo Therapeutics, Inc. the two are $1.16 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lexeo Therapeutics, Inc. Common Stock worth?
The market values Lexeo Therapeutics, Inc. at about $247M (market capitalisation, as of Nov 8, 2026). Per share that is $2.89; our models calculate a fair value of $1.73 per share.
What do the bullish and bearish scenarios say about LXEO?
Our models span a range for Lexeo Therapeutics, Inc.: cautious scenario $1.14, base $1.73, optimistic $2.15 per share (as of Nov 8, 2026, price $2.89). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lexeo Therapeutics, Inc. (LXEO)?
Balance-sheet figures for Lexeo Therapeutics, Inc. (as of Nov 8, 2026): return on equity −46.8%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is LXEO from its 52-week high?
Lexeo Therapeutics, Inc. trades at $2.89, about 73% below its 52-week high of $10.63 and 10% above the low of $2.63 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $1.73 is for.
Which stocks are comparable to Lexeo Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lexeo Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 8, 2026: price $2.89, calculated fair value $1.73 (−40%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LXEO calculated?
We run Lexeo Therapeutics, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.73 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Lexeo Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lexeo Therapeutics, Inc. (LXEO)?
The closing price on Nov 6, 2026 was $2.89. Our model-based fair value is $1.73, about 40% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lexeo Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($2.15). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.14 to $2.15) leaves room in how you read the outcome.

Key figures of Lexeo Therapeutics, Inc.

How large is the market capitalisation of Lexeo Therapeutics, Inc. (LXEO)?
The market capitalisation of Lexeo Therapeutics, Inc. is $247M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Lexeo Therapeutics, Inc. (LXEO)?
Earnings per share at Lexeo Therapeutics, Inc. are $−1.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Lexeo Therapeutics, Inc. (LXEO)?
The return on equity (ROE) of Lexeo Therapeutics, Inc. is −46.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lexeo Therapeutics, Inc. (LXEO)?
On an EBIT basis the return on assets of Lexeo Therapeutics, Inc. is −52.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Lexeo Therapeutics, Inc. (LXEO) generate?
The free cash flow of Lexeo Therapeutics, Inc. is −$99.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Lexeo Therapeutics, Inc. (LXEO) hold?
Lexeo Therapeutics, Inc. holds more cash than debt, $55.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Lexeo Therapeutics, Inc. Common Stock in the live analysis

One click puts Lexeo Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.